Voyager Therapeutics And AbbVie Announce Collaboration To Develop Vectorized Antibodies For Parkinson's Disease And Other Synucleinopathies; Voyager To Receiver $65M Upfront And Up To $245M In Preclinical Phase 1 Option Payments